Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Intrahepatic Cholangiocarcinoma
NCT03251443Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in intrahepatic cholangiocarcinoma (ICC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Progression-Free Survival at 6 months, Objective Response Rate at 1 year and 1 more. Started Aug 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03251443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251443.